Published in Health Business Week, August 20th, 2004
Including the special item, Albemarle's second-quarter 2004 net income was $20.8 million or 49 cents per share on a diluted basis. Included in Albemarle's second-quarter 2004 results is $2.9 million of realized foreign exchange hedging gains ($1.8 million after income taxes, or four cents per share on a diluted basis) associated with the company's planned acquisition of Akzo Nobel's refinery catalyst business.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.